Pharmacogenetic testing improves treatment responses in patients with PLA2R-related membranous nephropathy.
10.12122/j.issn.1673-4254.2023.06.23
- Author:
Tingting TAN
1
;
Yihou ZHENG
1
;
Yun LI
1
;
Youjia ZENG
1
Author Information
1. Shenzhen Traditional Chinese Medicine Hospital, Shenzhen 518000, China.
- Publication Type:Journal Article
- Keywords:
PLA2R-related membranous nephropathy;
immunosuppressive drugs;
personalized medicine;
pharmacogenomics
- MeSH:
Humans;
Autoantibodies;
Cyclosporine/therapeutic use*;
Glomerulonephritis, Membranous/diagnosis*;
Homozygote;
Immunosuppressive Agents/therapeutic use*;
Pharmacogenomic Testing;
Receptors, Phospholipase A2;
Sequence Deletion;
Serum Albumin;
Tacrolimus/therapeutic use*
- From:
Journal of Southern Medical University
2023;43(6):1047-1050
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the value of pharmacogenetic testing for improving the efficacy and safety of treatment with cyclosporine, tacrolimus, and cyclophosphamide (CTX) for PLA2R-related membranous nephropathy and for determing individualized and precise treatment plans for the patients.
METHODS:A total of 63 patients with PLA2R-related membranous nephropathy hospitalized in the Department of Nephrology at our hospital from January, 2019 to October, 2021 were enrolled in this study. Thirty-three of the patients underwent pharmacogenetic testing before taking the immunosuppressive drugs selected based on the results of genetic screening for sensitive targets, and the other 30 patients were empirically given immunosuppressive drugs according to the guidelines (control group). The clinical efficacy and adverse effects of the immunosuppressive drugs were analyzed for all the patients. The two groups of patients were compared for demographic and biochemical parameters including 24-h urine protein, serum albumin, renal function, and serum anti-phospholipase A2 receptor antibody both before and at 3 months after the beginning of the treatment.
RESULTS:Among the 33 patients undergoing pharmacogenetic testing, 51.5% showed a GG genotype for cyclosporine, and 61.6% had an AG genotype for tacrolimus; for CTX, 51.5% of the patients showed a homozygous deletion and 63.6% had an AA genotype. After treatment for 3 months, serum anti-phospholipase A2 receptor antibody, 24-h urine protein, and serum albumin levels were significantly improved in pharmacogenetic testing group as compared with the control group (P < 0.05).
CONCLUSION:Individualized and precise administration of immunosuppressive drugs based on pharmacogenetic testing better controls proteinuria and serum antiphospholipase A2 receptor antibodies and increases serum albumin level in patients with PLA2R-related membranous nephropathy.
